EUVIMEDEUVIMED entdecken
Open Access

Psychotropic Medication Prescribing for Children and Adolescents After the Onset of the COVID-19 Pandemic

Zaba Valtuille, Eric Acquaviva, Vincent Trebossen, Naim Ouldali, Aurelie Bourmaud, Stéphane Sclison, Alexandre Gomez, Alexis Revet, Hugo Peyre, Richard Delorme, Florentia Kaguelidou

JAMA Network Open · 23.04.2024 · 7 (4) · e247965

DOI: 10.1001/jamanetworkopen.2024.7965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 23.04.2024. Verfasst von Zaba Valtuille und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Investigations, Inserm CIC1426, Robert Debré University Hospital, APHP.Nord, Paris, France. Hauptthemen laut MEDLINE: COVID-19, Psychotropic Drugs, Pandemics, SARS-CoV-2. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Numerous studies have provided evidence for the negative associations of the COVID-19 pandemic with mental health, but data on the use of psychotropic medication in children and adolescents after the onset of the COVID-19 pandemic are lacking.

Objective

To assess the rates and trends of psychotropic medication prescribing before and over the 2 years after the onset of the COVID-19 pandemic in children and adolescents in France. Design, Setting, and Participants This cross-sectional study used nationwide interrupted time-series analysis of outpatient drug dispensing data from the IQVIA X-ponent database. All 8 839 143 psychotropic medication prescriptions dispensed to children (6 to 11 years of age) and adolescents (12 to 17 years of age) between January 2016 and May 2022 in France were retrieved and analyzed. Exposure Onset of COVID-19 pandemic. Main outcomes and Measures Monthly rates of psychotropic medication prescriptions per 1000 children and adolescents were analyzed using a quasi-Poisson regression before and after the pandemic onset (March 2020), and percentage changes in rates and trends were assessed. After the pandemic onset, rate ratios (RRs) were calculated between estimated and expected monthly prescription rates. Analyses were stratified by psychotropic medication class (antipsychotic, anxiolytic, hypnotic and sedative, antidepressant, and psychostimulant) and age group (children, adolescents).

Results

In total, 8 839 143 psychotropic medication prescriptions were analyzed, 5 884 819 [66.6%] for adolescents and 2 954 324 [33.4%] for children. In January 2016, the estimated rate of monthly psychotropic medication prescriptions was 9.9 per 1000 children and adolescents, with the prepandemic rate increasing by 0.4% per month (95% CI, 0.3%-0.4%). In March 2020, the monthly prescription rate dropped by 11.5% (95% CI, −17.7% to −4.9%). During the 2 years following the pandemic onset, the trend changed significantly, and the prescription rate increased by 1.3% per month (95% CI, 1.2%-1.5%), reaching 16.1 per 1000 children and adolescents in May 2022. Monthly rates of psychotropic medication prescriptions exceeded the expected rates by 11% (RR, 1.11 [95% CI, 1.08-1.14]). Increases in prescribing trends were observed for all psychotropic medication classes after the pandemic onset but were substantial for anxiolytics, hypnotics and sedatives, and antidepressants. Prescription rates rose above those expected for all psychotropic medication classes except psychostimulants (RR, 1.12 [95% CI, 1.09-1.15] in adolescents and 1.06 [95% CI, 1.05-1.07] in children for antipsychotics; RR, 1.30 [95% CI, 1.25-1.35] in adolescents and 1.11 [95% CI, 1.09-1.12] in children for anxiolytics; RR, 2.50 [95% CI, 2.23-2.77] in adolescents and 1.40 [95% CI, 1.30-1.50] in children for hypnotics and sedatives; RR, 1.38 [95% CI, 1.29-1.47] in adolescents and 1.23 [95% CI, 1.20-1.25] in children for antidepressants; and RR, 0.97 [95% CI, 0.95-0.98] in adolescents and 1.02 [95% CI, 1.00-1.04] in children for psychostimulants). Changes were more pronounced among adolescents than children. Conclusions and Relevance These findings suggest that prescribing of psychotropic medications for children and adolescents in France significantly and persistently increased after the COVID-19 pandemic onset. Future research should identify underlying determinants to improve psychological trajectories in young people.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Psychotropic DrugsPandemicsSARS-CoV-2HumansChildAdolescentMaleFemaleCross-Sectional StudiesFranceDrug PrescriptionsPractice Patterns, Physicians'Interrupted Time Series AnalysisAnti-Anxiety AgentsMental Disorders

Substanzen

Psychotropic DrugsAnti-Anxiety Agents

Autor:innen und Institutionen

  • Center of Clinical Investigations, Inserm CIC1426, Robert Debré University Hospital, APHP.Nord, Paris, France.
  • Paris Cité University, EA7323 Perinatal and Pediatric Pharmacology and Therapeutic Assessment, Paris, France.
  • Department of Child and Adolescent Psychiatry, Robert Debré University Hospital, APHP.Nord, Paris Cité University, Paris, France.
  • Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, APHP.Nord, Paris Cité University, Paris, France.
  • Clinical Epidemiology Unit, Inserm CIC1426, Robert Debré University Hospital, APHP.Nord, Paris Cité University, Paris, France.
  • Consulting Services & Analytics Department, IQVIA, Courbevoie, France.

Zitieren

APA

Valtuille, Z., Acquaviva, E., Trebossen, V., Ouldali, N., Bourmaud, A., Sclison, S., Gomez, A., Revet, A., Peyre, H., Delorme, R., & Kaguelidou, F. (2024). Psychotropic Medication Prescribing for Children and Adolescents After the Onset of the COVID-19 Pandemic. JAMA Network Open, 7(4), e247965. https://doi.org/10.1001/jamanetworkopen.2024.7965

Vancouver

Valtuille Z, Acquaviva E, Trebossen V, Ouldali N, Bourmaud A, Sclison S, et al. Psychotropic Medication Prescribing for Children and Adolescents After the Onset of the COVID-19 Pandemic. JAMA Network Open. 2024;7(4):e247965. doi:10.1001/jamanetworkopen.2024.7965

BibTeX
@article{Valtuille2024,
  author = {Valtuille, Zaba and Acquaviva, Eric and Trebossen, Vincent and Ouldali, Naim and Bourmaud, Aurelie and Sclison, Stéphane and Gomez, Alexandre and Revet, Alexis and Peyre, Hugo and Delorme, Richard and Kaguelidou, Florentia},
  title = {Psychotropic Medication Prescribing for Children and Adolescents After the Onset of the COVID-19 Pandemic},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {4},
  pages = {e247965},
  doi = {10.1001/jamanetworkopen.2024.7965}
}
Kostenlos starten →